ACTIVATION OF SYK TYROSINE KINASE PLAYS A ROLE IN RESISTANCE AGAINST THE SELECTIVE BTK INHIBITOR ONO/GS-4059 IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

被引：0
|
作者：
Tsukamoto, K. [1 ]
Harriet S, W. [1 ,2 ,3 ]
Sandrine, J. [1 ,3 ]
Dyer, M. J. [1 ,2 ,3 ]
机构：
[1] Univ Leicester, Canc Studies, Leicester, Leics, England
[2] Univ Leicester, Mol & Cell Biol, Leicester, Leics, England
[3] Univ Leicester, Ernest Waudby & Helen Scott Haematol Res Inst, Leicester, Leics, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1372
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [1] Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
    Kozaki, Ryohei
    Vogler, Meike
    Walter, Harriet S.
    Jayne, Sandrine
    Dinsdale, David
    Siebert, Reiner
    Dyer, Martin J. S.
    Yoshizawa, Toshio
    CANCERS, 2018, 10 (04)
  • [2] Discovery of a highly selective BTK inhibitor tirabrutinib(ONO/GS-4059) for B-cell lymphoma and inflammatory diseases
    Yamamoto, Shingo
    Suzuki, Ryo
    Hiramatsu, Atsushi
    Kijima, Hideomi
    Watanabe, Toshihide
    Egashira, Hiromu
    Takai, Shigeyuki
    Terakado, Masahiko
    Ogawa, Seiji
    Ima, Masaki
    Nishiyama, Taihei
    Doi, Issei
    Kurono, Masakuni
    Omi, Rie
    Kayasuga, Kana
    Kusuda, Shinya
    Imagawa, Akira
    Habashita, Hiromu
    Seko, Takuya
    Moriarty, Kevin
    Konteatis, Zenon
    Moffett, Kristofer
    Lee, Younghee
    Chao, Wenchun
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [3] PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
    Yahiaoui, Anella
    Meadows, Sarah A.
    Sorensen, Rick A.
    Cui, Zhi-Hua
    Keegan, Kathleen S.
    Brockett, Robert
    Chen, Guang
    Queva, Christophe
    Li, Li
    Tannheimer, Stacey L.
    PLOS ONE, 2017, 12 (02):
  • [4] A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
    Walter, Harriet S.
    Rule, Simon A.
    Dyer, Martin J. S.
    Karlin, Lionel
    Jones, Ceri
    Cazin, Bruno
    Quittet, Philippe
    Shah, Nimish
    Hutchinson, Claire V.
    Honda, Hideyuki
    Duffy, Kevin
    Birkett, Joseph
    Jamieson, Virginia
    Courtenay-Luck, Nigel
    Yoshizawa, Toshio
    Sharpe, John
    Ohno, Tomoya
    Abe, Shinichiro
    Nishimura, Akihisa
    Cartron, Guillaume
    Morschhauser, Franck
    Fegan, Christopher
    Salles, Gilles
    BLOOD, 2016, 127 (04) : 411 - 419
  • [5] Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059
    Walter, Harriet S.
    Jayne, Sandrine
    Rule, Simon A.
    Cartron, Guillaume
    Morschhauser, Franck
    Macip, Salvador
    Karlin, Lionel
    Jones, Ceri
    Herbaux, Charles
    Quittet, Philippe
    Shah, Nimish
    Hutchinson, Claire V.
    Fegan, Christopher
    Yang, Yingsi
    Mitra, Siddhartha
    Salles, Gilles
    Dyer, Martin J. S.
    BLOOD, 2017, 129 (20) : 2808 - 2810
  • [6] Single centre experience of a Bruton's tyrosine kinase (BTK) specific inhibitor (ONO-4059) in relapsed mantle cell lymphoma (MCL)
    Walter, H. S.
    Hutchinson, C. V.
    Sharpe, J.
    Duffy, K.
    Nishimura, A.
    Abe, S.
    Honda, H.
    Yasuhiro, T.
    Yoshizawa, T.
    Birkett, J.
    Courtenay-Luck, N.
    Dyer, M. J. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 58 - 59
  • [7] Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab
    Yasuhiro, Tomoko
    Sawada, Wako
    Klein, Christian
    Kozaki, Ryohei
    Hotta, Shingo
    Yoshizawa, Toshio
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 699 - 707
  • [8] Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
    Nagane, Motoo
    Narita, Yoshitaka
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2019, 134
  • [9] Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
    Rule, Simon A.
    Cartron, Guillaume
    Fegan, Christopher
    Morschhauser, Franck
    Han, Lingling
    Mitra, Siddhartha
    Salles, Gilles
    Dyer, Martin J. S.
    LEUKEMIA, 2020, 34 (05) : 1458 - 1461
  • [10] The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
    Dasmahapatra, Girija
    Patel, Hiral
    Dent, Paul
    Fisher, Richard I.
    Friedberg, Jonathan
    Grant, Steven
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) : 43 - 56
12345